COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern
Mon, 31 Mar 2025 05:01:00 GMT Following the negative results of the COAST Phase 3 trial announced on 24 March 2025, Opthea determined that the most appropriate course of action for wet AMD patients, shareholders, and other ...
Sun, 30 Mar 2025 20:45:00 GMT Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its second Phase 3 trial ShORe in patients with wet AMD.
Sun, 30 Mar 2025 17:00:00 GMT Following the negative results of the COAST Phase 3 trial announced on 24 March 2025, Opthea determined that the most appropriate course of action for wet AMD patients, shareholders, and other ...
Sun, 30 Mar 2025 17:00:00 GMT After announcing that lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD), Opthea has now decided to close the Coast trial as well as ...
Mon, 24 Mar 2025 05:33:00 GMT In a phase III trial enrolling close to 1000 candidates dubbed Coast, Opthea had been testing the efficacy of its drug sozinibercept, for wet aged-related macular degeneration (wet AMD).
